BioLife Solutions, Inc.
NASDAQ:BLFSMedical - Instruments & Supplies
+$0.40 today
- Market cap
- $1.89B
- Beta
- 1.97
- P/E (TTM)
- -119.9
- EPS (TTM)
- -$0.22
Volume 4.39M
Average 0.52M
BLFS Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
BioLife Solutions, Inc.NASDAQ: BLFS
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $17.38M rose 2.2% year over year, behind the +94.5% change in trailing-twelve-month operating expenses. Sequentially, it rose 153.5% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.
Context
- Operating expenses amounted to 77.2% of revenue in FY2025, up 3.3 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +2.2% toward the trailing-twelve-month pace of +94.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 74.25M USD
- Year-over-year change
- +22.1%
- 4-year CAGR
- +0.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.25M | +22.1% |
| FY2024 | 2024-12-31 | 60.8M | -48.3% |
| FY2023 | 2023-12-31 | 117.58M | +122.5% |
| FY2022 | 2022-12-31 | 52.83M | -28.0% |
| FY2021 | 2021-12-31 | 73.34M | — |
Operating Expenses vs competitors
How BLFS compares with its peers on the latest reported figures
- BLFS's LTM Mar 2026 operating expenses of $74.63M is the lowest of the 11 companies compared; the peer median is $274.72M.
- Its year-over-year change of +94.5% is the highest of 11, against a peer median of +10.2%.
- Operating expenses amounts to 74.8% of revenue for BLFS, versus a peer median of 75.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $690.48M | +6.8% | +7.8% | 102.4% | |
| LTM Sep 2026 | $447.31M | +59.0% | +12.5% | 71.9% | |
| LTM Aug 2026 | $426.36M | +16.9% | +5.3% | 48.2% | |
| LTM Jun 2026 | $419.96M | +3.0% | +11.6% | 73.7% | |
| LTM Apr 2026 | $322.49M | -4.5% | -1.5% | 65.1% | |
| LTM Apr 2026 | $226.94M | -17.3% | +8.3% | 78.2% | |
| LTM Sep 2026 | $202.65M | +9.5% | +8.2% | 76.8% | |
| LTM Jan 2026 | $184.42M | +91.1% | — | 220.3% | |
| LTM Mar 2026 | $170.99M | +10.9% | +39.3% | 63.6% | |
| LTM Jun 2026 | $82.79M | +15.0% | +17.4% | 6986.2% | |
| LTM Mar 2026 | $74.63M | +94.5% | +12.0% | 74.8% | |
| Peer median (excluding BLFS) | $274.72M | +10.2% | +8.3% | 75.2% | |
Competitors are the stored peer set for BLFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M |
| Cost of Revenue | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M |
| Gross Profit | 28.85M | 46.91M | 46.75M | 53.67M | 62.12M |
| Gross Margin | 24.2% | 61.5% | 61.6% | 65.3% | 64.6% |
| Research & Development | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M |
| Selling, General & Admin | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M |
| Operating Expenses | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M |
| Depreciation & Amortization | 12.87M | 19.96M | 12.3M | 8.66M | 4.69M |
| EBITDA | (16.65M) | (124.18M) | (45.24M) | 1.53M | 3.61M |
| EBITDA Margin | -14.0% | -162.9% | -59.6% | 1.9% | 3.7% |
| Operating Income | (35.16M) | (5.92M) | (23.44M) | (7.13M) | (1.08M) |
| Operating Margin | -29.5% | -7.8% | -30.9% | -8.7% | -1.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 485K | 687K | 1.81M | 719K | 2.71M |
| Other Income / Expenses | 6.13M | 1.08M | 4.97M | (4.3M) | (11M) |
| Income Before Tax | (29.03M) | (4.85M) | (18.47M) | (11.43M) | (12.08M) |
| Pre-Tax Margin | -24.4% | -6.4% | -24.4% | -13.9% | -12.6% |
| Income Tax Expense | (20.12M) | (5.24M) | 24K | (38K) | 49K |
| Net Income | (8.91M) | (139.81M) | (66.43M) | (20.18M) | (12.13M) |
| Net Margin | -7.5% | -183.4% | -87.6% | -24.5% | -12.6% |
| EPS (Basic) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| EPS (Diluted) | (0.23) | (3.29) | (1.52) | (0.44) | (0.25) |
| Weighted Avg Shares | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M |
| Weighted Avg Shares (Diluted) | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M |
BioLife Solutions, Inc.
NASDAQ:BLFS
Intrinsic Alpha fair value
Locked
Current Price
$38.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.